Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin rebounds near $83K but faces strong resistance below its 2025 peak around $90K-$94K.

Market News
19 Oct 2026
Coinpaper
View Source
Neutral
Bitcoin rebounds near $83K but faces strong resistance below its 2025 peak around $90K-$94K.

Bitcoin has recovered to about $82,800 in October after a turbulent year, yet it remains 34% below its October 2025 peak near $126,000. Coinbase highlights a major resistance zone between $89,600 and $93,700, where 1.7 million BTC are held, suggesting difficulty breaking above $90,000. Institutional demand, especially from U.S. spot Bitcoin ETFs, shows recent outflows but remains strong overall, while Federal Reserve policies and bond yields continue to influence market conditions. The coming weeks, including the Fed's October 28 decision, will be crucial in determining if Bitcoin can rally further before 2026 ends.

Bitcoin price prediction is the subject, with a key context that it remains 34% below its October 2025 peak near $126,000. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Oct 19, 2026 18:21 WIB: out of 50 major cryptocurrencies, 23 rose and 25 fell today. Notable movers include AXS at Rp18.020 with 100% buy orders, AAVE at Rp2.711.732 with 60% buy orders, and MANA at Rp1.511 with 53% buy orders.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
55 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
55 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
55 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
55 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
55 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App